276 related articles for article (PubMed ID: 19879424)
1. Clusterin and chemoresistance.
Djeu JY; Wei S
Adv Cancer Res; 2009; 105():77-92. PubMed ID: 19879424
[TBL] [Abstract][Full Text] [Related]
2. Induction of clusterin by AKT--role in cytoprotection against docetaxel in prostate tumor cells.
Zhong B; Sallman DA; Gilvary DL; Pernazza D; Sahakian E; Fritz D; Cheng JQ; Trougakos I; Wei S; Djeu JY
Mol Cancer Ther; 2010 Jun; 9(6):1831-41. PubMed ID: 20501799
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of secretory clusterin (sCLU) induces chemotherapy resistance in human gastric cancer cells by targeting miR-195-5p.
Mu L; Yang F; Guo D; Li P; Zhang M
Bioengineered; 2020 Dec; 11(1):472-483. PubMed ID: 32250192
[TBL] [Abstract][Full Text] [Related]
4. Intracellular clusterin inhibits mitochondrial apoptosis by suppressing p53-activating stress signals and stabilizing the cytosolic Ku70-Bax protein complex.
Trougakos IP; Lourda M; Antonelou MH; Kletsas D; Gorgoulis VG; Papassideri IS; Zou Y; Margaritis LH; Boothman DA; Gonos ES
Clin Cancer Res; 2009 Jan; 15(1):48-59. PubMed ID: 19118032
[TBL] [Abstract][Full Text] [Related]
5. Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer.
Zoubeidi A; Chi K; Gleave M
Clin Cancer Res; 2010 Feb; 16(4):1088-93. PubMed ID: 20145158
[TBL] [Abstract][Full Text] [Related]
6. Roles of clusterin in progression, chemoresistance and metastasis of human ovarian cancer.
Wei L; Xue T; Wang J; Chen B; Lei Y; Huang Y; Wang H; Xin X
Int J Cancer; 2009 Aug; 125(4):791-806. PubMed ID: 19391138
[TBL] [Abstract][Full Text] [Related]
7. Clusterin confers resistance to TNF-alpha-induced apoptosis in breast cancer cells through NF-kappaB activation and Bcl-2 overexpression.
Wang Y; Wang X; Zhao H; Liang B; Du Q
J Chemother; 2012 Dec; 24(6):348-57. PubMed ID: 23174100
[TBL] [Abstract][Full Text] [Related]
8. CLU blocks HDACI-mediated killing of neuroblastoma.
Subramanian C; Jarzembowski JA; Halsey SM; Kuick R; Opipari AW; Castle VP; Kwok RP
Tumour Biol; 2011 Apr; 32(2):285-94. PubMed ID: 21042904
[TBL] [Abstract][Full Text] [Related]
9. Clusterin facilitates COMMD1 and I-kappaB degradation to enhance NF-kappaB activity in prostate cancer cells.
Zoubeidi A; Ettinger S; Beraldi E; Hadaschik B; Zardan A; Klomp LW; Nelson CC; Rennie PS; Gleave ME
Mol Cancer Res; 2010 Jan; 8(1):119-30. PubMed ID: 20068069
[TBL] [Abstract][Full Text] [Related]
10. Secretory Clusterin: A Promising Target for Chemoresistance of Hepatocellular Carcinoma.
Zhang J; Wu M; Xu Y; Song Q; Zheng W
Mini Rev Med Chem; 2020; 20(12):1153-1165. PubMed ID: 32228422
[TBL] [Abstract][Full Text] [Related]
11. Secreted clusterin gene silencing enhances chemosensitivity of a549 cells to cisplatin through AKT and ERK1/2 pathways in vitro.
Zhang B; Zhang K; Liu Z; Hao F; Wang M; Li X; Yin Z; Liang H
Cell Physiol Biochem; 2014; 33(4):1162-75. PubMed ID: 24751980
[TBL] [Abstract][Full Text] [Related]
12. HMGB1 induction of clusterin creates a chemoresistant niche in human prostate tumor cells.
Zhou J; Chen X; Gilvary DL; Tejera MM; Eksioglu EA; Wei S; Djeu JY
Sci Rep; 2015 Oct; 5():15085. PubMed ID: 26469759
[TBL] [Abstract][Full Text] [Related]
13. Glyceryl trinitrate‑induced cytotoxicity of docetaxel‑resistant prostatic cancer cells is associated with differential regulation of clusterin.
Bouaouiche S; Magadoux L; Dondaine L; Reveneau S; Isambert N; Bettaieb A; Jeannin JF; Laurens V; Plenchette S
Int J Oncol; 2019 Apr; 54(4):1446-1456. PubMed ID: 30720069
[TBL] [Abstract][Full Text] [Related]
14. The role of clusterin (CLU) in malignant transformation and drug resistance in breast carcinomas.
Redondo M; Tellez T; Roldan MJ
Adv Cancer Res; 2009; 105():21-43. PubMed ID: 19879421
[TBL] [Abstract][Full Text] [Related]
15. Clusterin, a Novel DEC1 Target, Modulates DNA Damage-Mediated Cell Death.
Ming X; Bao C; Hong T; Yang Y; Chen X; Jung YS; Qian Y
Mol Cancer Res; 2018 Nov; 16(11):1641-1651. PubMed ID: 30002194
[TBL] [Abstract][Full Text] [Related]
16. Small interfering RNA targeted to secretory clusterin blocks tumor growth, motility, and invasion in breast cancer.
Niu Z; Li X; Hu B; Li R; Wang L; Wu L; Wang X
Acta Biochim Biophys Sin (Shanghai); 2012 Dec; 44(12):991-8. PubMed ID: 23099883
[TBL] [Abstract][Full Text] [Related]
17. Secretory clusterin (sCLU) overexpression is associated with resistance to preoperative neoadjuvant chemotherapy in primary breast cancer.
Niu ZH; Wang Y; Chun B; Li CX; Wu L
Eur Rev Med Pharmacol Sci; 2013 May; 17(10):1337-44. PubMed ID: 23740447
[TBL] [Abstract][Full Text] [Related]
18. The chaperone activity of clusterin is dependent on glycosylation and redox environment.
Rohne P; Prochnow H; Wolf S; Renner B; Koch-Brandt C
Cell Physiol Biochem; 2014; 34(5):1626-39. PubMed ID: 25402950
[TBL] [Abstract][Full Text] [Related]
19. CLU and colon cancer. The dual face of CLU: from normal to malignant phenotype.
Mazzarelli P; Pucci S; Spagnoli LG
Adv Cancer Res; 2009; 105():45-61. PubMed ID: 19879422
[TBL] [Abstract][Full Text] [Related]
20. Secretory clusterin promotes oral cancer cell survival via inhibiting apoptosis by activation of autophagy in AMPK/mTOR/ULK1 dependent pathway.
Naik PP; Mukhopadhyay S; Praharaj PP; Bhol CS; Panigrahi DP; Mahapatra KK; Patra S; Saha S; Panda AK; Panda K; Paul S; Aich P; Patra SK; Bhutia SK
Life Sci; 2021 Jan; 264():118722. PubMed ID: 33160989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
